ESMO GI 2026

July 01-04, 2026
Munich, Germany

ESMO Gastrointestinal Cancers Annual Congress 2026
Explore more Oncology congress materials
Material Type

Results(4)

Oncology
Health-related quality of life with zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive advanced/metastatic gastro-oesophageal adenocarcinoma: Results from HERIZON-GEA-01
Author(s): Kohei Shitara, Elena Elimova, Lin Shen et al.
HERIZON-GEA-01: Exploratory Analysis of Response Characteristics and PFS2 in Advanced or Metastatic Gastroesophageal Adenocarcinoma
Author(s): Filippo Pietrantonio, Kohei Shitara, Tianshu Liu et al.
Consensus Guidance for Management of Diarrhoea With Zanidatamab + Chemotherapy 1–4 July 2026 – Munich, Germany ± Tislelizumab in First-Line Advanced/Metastatic Gastroesophageal Adenocarcinoma: A Modified Delphi Panel Study
Author(s): Kohei Shitara, Jaffer A. Ajani, Filippo Pietrantonio et al.
Quantitative medicine analyses of zanidatamab dose regimens in patients with HER2-positive locally advanced/metastatic gastro-oesophageal adenocarcinoma
Author(s): Filip Van Herpe, Josep Tabernero, Geoffrey Ku et al.